Inflammatory bowel diseases
Cure8 research brief
Why This Matters
People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or continuing biologics or small molecules, and when managing IBD around a cancer diagnosis.
Who Should Pay Attention
Adults with IBD (Crohn's disease or ulcerative colitis), patients on or considering biologics or small molecules, clinicians managing IBD with concurrent or prior malignancy, and researchers studying therapy safety.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The review found reassuring overall safety for anti-TNF agents as monotherapy, vedolizumab, and ustekinumab, though uncertainty remains about lymphoma and melanoma risk when anti-TNFs are combined with thiopurines. Early data for selective anti–IL-23 drugs look promising but are still limited.
When prior or active cancer is present, the evidence is mainly observational; decisions should be individualized in multidisciplinary teams and may include temporary IBD treatment withdrawal during cancer therapy. Data on JAK inhibitors and S1P modulators are sparse, supporting a cautious approach, especially for older or high‑risk patients.
Keep In Mind
This article is a review (abstract-level extraction) summarizing observational studies and early trial data. Findings are limited by confounding, heterogeneous populations, and short follow-up for some newer agents; it does not replace individualized clinical decision-making.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory bowel diseases
AuthorsJavier P Gisbert, María Chaparro
InstitutionGastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 25, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Systematic Review of Malignancy Risk with Biologic, Advanced Small-Molecule, and Thiopurine Therapies for Inflammatory Bowel Disease
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.